Retained Rights. As between the Parties and subject to the licenses in this OEM Agreement, [[PTC:Organization]] owns all rights in the [[PTC:Organization]] Products, including all [[PTC:Organization]] Distributable Software, and RA owns all rights in the RA Products, including all RA Distributable Software, provided to [[PTC:Organization]], including in either case all Updates, upgrades, modules, add-ons, modifications or improvements to or derivative works. Each Party retains all rights, titles, and interests in and to its respective technology and intellectual property, including the intellectual property rights in its trademarks, products, services, and documentation, and hereby reserves all rights not expressly granted in this OEM Agreement or the Strategic Alliance Agreement. Except as set forth herein, neither Party will attempt to or knowingly permit or encourage others to, and each Party will cause its Affiliates not to, attempt to alter, reverse engineer, decompile, disassemble or otherwise attempt to derive the source code of the other Party’s materials, except to the extent that the restrictions in this sentence are expressly precluded by applicable laws. Taking any of these actions is a material breach of this OEM Agreement.

Retained Rights. Notwithstanding any provision to the contrary set forth in this Agreement, Cyclerion (on behalf of itself and its licensees, other than Akebia and its Sublicensees) expressly retains the right under the Cyclerion Intellectual Property to # exercise its rights and perform its obligations under this Agreement, # Manufacture the Licensed Compounds and Products (including the right to Develop, Manufacture, make, use or import ​ and all other intermediates and precursors to the Licensed Compounds and the Products for the purposes of Manufacturing Licensed Compound and Products) solely for the purpose of supplying the same to Akebia or its Affiliates in accordance with this Agreement, and # Exploit ​ and all other intermediates and precursors to the Licensed Compounds and the Products for the purpose of Exploiting compounds and products that are not Licensed Compounds or Products. Any rights not expressly granted to Akebia by Cyclerion under this Agreement are hereby retained by Cyclerion.

Retained Rights. Notwithstanding the exclusivity of the License or any portion thereof, Verrica hereby expressly reserves:

For clarity, Atea retains the exclusive ownership and right to use any compound that was generated by or on behalf of Atea, or that is otherwise Covered by intellectual property rights Controlled by Atea, at the Effective Date or during the Agreement Term in the Excluded Field.

Retained Rights. IMMEDICA acknowledges and agrees that LICENSOR retains the right: # to make, have made and use the Product for internal research purposes within the Field in the Territory, provided such reservation of rights is non-sublicensable and non-transferable and expressly excludes # the right to conduct clinical studies in the Territory for Arginase 1 Deficiency other than those expressly permitted under this Agreement or as otherwise agreed by the Parties in writing, # the right to apply for or to seek Regulatory Approval in the Territory, and # the right to Commercialize the Product in the Territory, and # for any and all purposes outside of the Territory. Notwithstanding the foregoing, in the event that LICENSOR or its Affiliates, or any party acting on their behalf, decides to conduct any clinical studies in the Territory which use the Product, then the LICENSOR shall promptly consult in good faith with IMMEDICA and shall provide a copy of the relevant protocol for IMMEDICA’s prior review and comment prior to commencing any such clinical study, and any such IMMEDICA comments will be considered by the LICENSOR in good faith.

Retained Rights. Notwithstanding the exclusive license granted to BMS pursuant to [Section 5.1.1, MTEM]M] hereby expressly reserves the right # under the MTEM Licensed Know-How and MTEM Licensed Patents to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more Affiliates or permitted subcontractors, and # to practice, and to grant licenses under, the MTEM Licensed Know-How and MTEM Licensed Patents, other than # Optioned Product-Specific Patents, # BMS Binder

Retained Rights. Nothing in this Waiver shall result in any waiver, release, discharge or effect of any kind upon # my rights to indemnification and the advancement of expenses as an officer and/or director of [[Verso:Organization]] and/or as a director or officer of any of its subsidiaries as set forth in [[Verso:Organization]]’s Amended and Restated Bylaws, the constituent documents of its subsidiaries, or the Indemnification Agreement dated as of ​, between [[Verso:Organization]] and me, to the maximum extent provided therein, # my entitlement to protection under any and all insurance policies that [[Verso:Organization]] may elect to maintain generally for the benefit of its directors and officers against all costs, charges and expenses incurred or sustained by me in connection with any action, suit or proceeding to which I may be made a party by reason of my being or having been a director, officer or employee of [[Verso:Organization]] or any of its subsidiaries (other than any dispute, claim or controversy arising under or relating to the Agreement or this Waiver); or # any dispute, claim or controversy arising under this Waiver.

Retained Rights. Evoke reserves the right to discontinue developing or producing the Product at its discretion at any time and for any reason, including due to legal or regulatory requirements, administrative or court orders, or safety risks; provided, however, that Evoke shall notify Eversana in writing as soon as practicable after any such proposed or anticipated discontinuance. Notwithstanding Section 2.1 or any other provision of this Agreement, Evoke will retain the exclusive right to Manufacture or have Manufactured and supply the Product in and outside the Territory. In addition, Evoke shall retain the right to develop the Product in the Territory and outside the Territory and the right to Commercialize the Product inside and outside the Territory.

Retained Rights. [[Agenus:Organization]] retains all rights to use the Licensed IP except those expressly granted to Betta under the terms of this Agreement. Without limiting the foregoing, the Parties agree that [[Agenus:Organization]] and its Affiliates will retain the rights under the Licensed IP for [[Agenus:Organization]] and its Affiliates to # Exploit the Licensed Antibodies and/or Licensed Products ​ in all fields outside the Territory and outside the Field in the Territory, # Develop and Manufacture the Licensed Antibodies and/or Licensed Products ​ in the Territory solely for the Exploitation outside the Territory of such Licensed Antibodies and/or Licensed Products, but in no event for the Commercialization of such Licensed Antibodies and/or Licensed Products in the Field and in the Territory, and # research the Licensed Antibodies and/or Licensed Products ​ in or outside the Territory (collectively, the “Retained Rights”).

Retained Rights. In addition to any other rights retained by Stoke hereunder with respect to the Stoke [[Unknown Identifier]] Technology, Stoke ​ Technology and Stoke [[Unknown Identifier]] Technology, and subject to the terms and conditions set forth herein, including Section 2.5, Stoke retains the exclusive right to practice, license and otherwise exploit the Stoke [[Unknown Identifier]] Technology, Stoke ​ Technology and Stoke [[Unknown Identifier]] Technology in the Territory outside the scope of the licenses granted under Section 2.1, including with respect to products other than the Products. In addition to any other rights retained by Acadia hereunder with respect to the Acadia [[Unknown Identifier]] Technology, and subject to the terms and conditions set forth herein, including Section 2.5, Acadia retains the exclusive right to practice, license and otherwise exploit the Acadia [[Unknown Identifier]] Technology in the Territory outside the scope of the licenses granted under [Section 2.1(c)(ii)], including with respect to products other than the [[Unknown Identifier]] Co-Co Products. For clarity, the licenses granted to Acadia under Section 2.1 do not extend to Other Active Ingredients that may be covered by Stoke [[Unknown Identifier]] Technology, Stoke ​ Technology or Stoke [[Unknown Identifier]] Technology.